Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research

Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research

A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled-out in low-income and middle-income countries (LMICs). Studies from predominantly high-income settings have found that dolutegravir-based regimens have superior efficacy, tolerability and durability compare...

Bibliografske podrobnosti
Main Authors:	Dorward, J, Lessells, R, Drain, P, Naidoo, K, De Oliveira, T, Pillay, Y, Abdool Karim, S, Garrett, N
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2018

Podobne knjige/članki

Viremia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy
od: Dorward, J, et al.
Izdano: (2024)

Clinical outcomes after Viremia among people receiving dolutegravir vs efavirenz-based first-line antiretroviral therapy in South Africa
od: Asare, K, et al.
Izdano: (2023)

Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens
od: Inzaule, SC, et al.
Izdano: (2019)

Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study
od: Dorward, J, et al.
Izdano: (2023)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
od: Dorward, J, et al.
Izdano: (2023)

Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy
od: Dorward, J, et al.
Izdano: (2023)

HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
od: Gupta, RK, et al.
Izdano: (2017)

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study
od: Asare, K, et al.
Izdano: (2023)

Antibiotic consumption in low-income and middle-income countries
od: Hamers, R, et al.
Izdano: (2018)

Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach
od: Tenforde, M, et al.
Izdano: (2019)

Tackling antimicrobial resistance in low-income and middle-income countries
od: Pokharel, S, et al.
Izdano: (2019)

HIV drug resistance in low-income and middle-income countries
od: Hamers, R, et al.
Izdano: (2018)

Epilepsy stigma in children in low-income and middle-income countries
od: Kariuki, SM, et al.
Izdano: (2021)

Point-of-care viral load testing to manage HIV viraemia during the rollout of dolutegravir-based ART in South Africa: a randomised feasibility study (POwER)
od: Dorward, J, et al.
Izdano: (2023)

Mental health interventions in schools in low-income and middle-income countries
od: Fazel, M, et al.
Izdano: (2014)

Achieving affordable critical care in low-income and middle-income countries
od: Turner, H, et al.
Izdano: (2019)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
od: Keene, CM, et al.
Izdano: (2023)

Reducing the burden of road traffic injury: translating high-income country interventions to middle-income and low-income countries
od: Stevenson, M, et al.
Izdano: (2008)

Dolutegravir in sub-Saharan Africa: context is crucial
od: Dorward, J, et al.
Izdano: (2018)

End COVID-19 in low- and middle-income countries
od: Mobarak, AM, et al.
Izdano: (2022)

Neurodevelopmental disorders in low- and middle-income countries
od: Newton, C
Izdano: (2012)

Molecular Pharming for low and middle income countries
od: Murad, S, et al.
Izdano: (2019)

Antimicrobial stewardship in low- and middle-income countries
od: Gyssens, IC, et al.
Izdano: (2020)

Kidney care in low- and middle-income countries
od: Qarni, B, et al.
Izdano: (2019)

Neurodevelopmental disorders in low- and middle-income countries.
od: Newton, C
Izdano: (2012)

Barriers to improvement of mental health services in low-income and middle-income countries.
od: Saraceno, B, et al.
Izdano: (2007)

Protecting children in low-income and middle-income countries from COVID-19
od: Ahmed, S, et al.
Izdano: (2020)

Systematic review of barriers to surgical care in low-income and middle-income countries
od: Grimes, C, et al.
Izdano: (2011)

Systematic review of barriers to surgical care in low-income and middle-income countries.
od: Grimes, C, et al.
Izdano: (2011)

Developing guidelines in low-income and middle-income countries: lessons from Kenya
od: English, M, et al.
Izdano: (2017)

Implementing change for facility-based peripartum care in low-income and middle-income countries
od: Aluvaala, J, et al.
Izdano: (2020)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
od: Keene, CM, et al.
Izdano: (2021)

Pneumococcal conjugate vaccine implementation in middle-income countries
od: Tricarico, Serena, et al.
Izdano: (2017)

Impact of corruption on financial development in middle income countries
od: Haw, Meng Jie
Izdano: (2012)

Packages of care for epilepsy in low- and middle-income countries.
od: Mbuba, C, et al.
Izdano: (2009)

Vaccine-preventable diseases in lower-middle-income countries
od: Turner, H, et al.
Izdano: (2018)

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
od: Zhao, Y, et al.
Izdano: (2021)

Early antiretroviral therapy is associated with better viral suppression and less HIV drug resistance after implementation of universal treatment in South Africa
od: Dorward, J, et al.
Izdano: (2019)

Cost-effectiveness of club-foot treatment in low-income and middle-income countries by the Ponseti method
od: Grimes, C, et al.
Izdano: (2016)

Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries
od: Mendelson, M, et al.
Izdano: (2015)